Zydus, formerly known as Cadila Healthcare, was hit with a trio of agency observations at one of its Indian manufacturing facilities
India-based Zydus Lifesciences has been mentioned by the US FDA for unnamed violations at an injectables facility.
According to a report in fiercepharma.com, a recent FDA inspection, Zydus, formerly known as Cadila Healthcare, was hit with a trio of agency observations at one of its Indian manufacturing facilities. The regulator issued the write-up to Zydus’ injectables plant in Jarod, Gujarat, India, which it inspected between February 24 and March 10.
In a corporate communique issued last week, Zydus said it was confident about “addressing and resolving the issues to the satisfaction of the USFDA,” without clarifying what those issues were. “We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network,” the company continued in its filing.
Zydus in 2019 received 11 FDA observations at its Nesher finished dose facility in St. Louis. Again in 2019, Zydus said that a two-week FDA inspection of its Moraiya, India, formulation facility yielded 14 observations
The Indian company has had many problems with the FDA in recent years. Last March, Zydus’ US generics unit recalled four lots of acyclovir sodium injection 50mg/mL, which is used to treat herpes and shingles, after it received “several complaints” of crystallization in vials.
At that time, Zydus said it had not received any side effect reports linked to the recall, though the use of crystalized acyclovir could be fatal, the company warned. Particulate matter moving through the bloodstream can cause clots that trigger strokes or heart attacks, decrease liver or kidney function, or kill tissues or cells, Zydus said.
Also, Zydus in 2019 received 11 FDA observations at its Nesher finished dose facility in St. Louis. Again in 2019, Zydus said that a two-week FDA inspection of its Moraiya, India, formulation facility yielded 14 observations. In November, the FDA slapped Zydus’ Moraiya plant with a warning letter, which flagged “significant cross-contamination” issues.
******************************************************
Readers
These are extraordinary times. All of us have to rely on high-impact, trustworthy journalism. And this is especially true of the Indian Diaspora. Members of the Indian community overseas cannot be fed with inaccurate news.
Pravasi Samwad is a venture that has no shareholders. It is the result of an impassioned initiative of a handful of Indian journalists spread around the world. We have taken the small step forward with the pledge to provide news with accuracy, free from political and commercial influence. Our aim is to keep you, our readers, informed about developments at ‘home’ and across the world that affect you.
Please help us to keep our journalism independent and free.
In these difficult times, to run a news website requires finances. While every contribution, big or small, will makes a difference, we request our readers to put us in touch with advertisers worldwide. It will be a great help.
For more information: pravasisamwad00@gmail.com